These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 8252509

  • 1. Combination treatment in M1 prostate cancer.
    Ferrari P, Castagnetti G, Ferrari G, Pollastri CA, Tavoni F, Dotti A.
    Cancer; 1993 Dec 15; 72(12 Suppl):3880-5. PubMed ID: 8252509
    [Abstract] [Full Text] [Related]

  • 2. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O'Donoghue EP, Sikora K.
    Am J Clin Oncol; 1988 Dec 15; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [Abstract] [Full Text] [Related]

  • 3. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
    Doberauer C, Niederle N, Schmidt CG.
    Cancer; 1988 Aug 01; 62(3):474-8. PubMed ID: 3134119
    [Abstract] [Full Text] [Related]

  • 4. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H, Senge T.
    J Urol; 1990 Oct 01; 144(4):934-41. PubMed ID: 2144596
    [Abstract] [Full Text] [Related]

  • 5. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH, Lock TM, Chadha DR, Debruyne FM, Karthaus HF, de Jong FH, Klijn JG, Matroos AW, de Voogt HJ.
    J Urol; 1987 May 01; 137(5):912-8. PubMed ID: 2952810
    [Abstract] [Full Text] [Related]

  • 6. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A.
    Urol Int; 1996 May 01; 56 Suppl 1():13-7. PubMed ID: 8776812
    [Abstract] [Full Text] [Related]

  • 7. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F, Serio M, D'Eramo G, Sciarra F.
    Eur Urol; 1990 May 01; 18 Suppl 3():54-61. PubMed ID: 2151278
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD, Horlbeck R, Klippel KF.
    Semin Oncol; 1991 Oct 01; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [Abstract] [Full Text] [Related]

  • 10. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP.
    J Urol; 1991 Nov 01; 146(5):1321-6. PubMed ID: 1834864
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
    de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M.
    J Steroid Biochem Mol Biol; 1990 Dec 20; 37(6):965-9. PubMed ID: 2149509
    [Abstract] [Full Text] [Related]

  • 13. Buserelin in the treatment of prostatic cancer.
    Roila F.
    Biomed Pharmacother; 1989 Dec 20; 43(4):279-85. PubMed ID: 2506941
    [Abstract] [Full Text] [Related]

  • 14. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Klijn JG, de Voogt HJ, Studer UE, Schröder FH, Sylvester R, De Pauw M.
    Cancer; 1993 Dec 15; 72(12 Suppl):3858-62. PubMed ID: 8252504
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
    Fourcade RO, Cariou G, Coloby P, Colombel P, Coulange C, Grise P, Mangin P, Soret JY, Poterre M.
    Eur Urol; 1990 Dec 15; 18 Suppl 3():45-7. PubMed ID: 2151276
    [Abstract] [Full Text] [Related]

  • 17. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
    Iversen P.
    Eur Urol; 1990 Dec 15; 18 Suppl 3():41-4. PubMed ID: 2151275
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
    Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, Cortellini P.
    Eur Urol; 1990 Dec 15; 18 Suppl 3():48-53. PubMed ID: 2151277
    [Abstract] [Full Text] [Related]

  • 20. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B, Varenhorst E, Petas A, Sandow J.
    Eur Urol; 2006 Sep 15; 50(3):483-9. PubMed ID: 16626856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.